| Revenue Growth | Q3 revenue $4M vs $2.2M; YTD $31.8M vs $10.3M. |
|---|---|
| Mgmt Confidence | High confidence; raised 2026 revenue and cash outlook for second time. |
| Demand Visibility | 111 active partners; 433 active programs; $3B total contracted potential milestones. |
| Margin Trends | Exploration consumables/software expected to drive high-margin recurring revenue streams. |
| Op. Leverage | Lowered 2026 OpEx guidance to $83M-$87M due to found efficiencies. |
| Pricing Power | Average royalty rate of 3.4% across 433 active programs. |
| Vol vs Price | Growth driven by milestone volume and new high-value service contracts. |
| Segment Growth | Exploration revenue $2M-$3M in 2026; service revenue up on ion-channels. |
| New Clients | Eli Lilly, Yamaya Inc., and Monash University added as new partners. |
| Capex & Debt | Year-end cash guidance $53M-$57M; business expected to be cash break-even. |
| Regulatory | Baticlimab received approval in China for generalized myasthenia gravis. |
| Commentary | Emphasized 'Biological Intelligence' and AI-powered discovery via OmniDeep and Exploration platforms. |
| New Launches | Launched OmniTides for peptide discovery and expanded commercial access to Exploration. |
Growth
Q3 revenue grew to $4M from $2.2M; year-to-date revenue reached $31.8M.
Outlook
Raised 2026 revenue guidance to $35M-$39M; exploration revenue expected to double in 2027.
Risks
Management used vague language regarding specific royalty pricing for Baticlimab and exploration consumable pull-through rates.
The company's earnings call, NASDAQ: OABI, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
OmniAb, Inc.: key numbers
- Share price
- $4.89Close, Nov 16
- Market cap
- $713M
- Shares outstanding
- 145.86MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Commercial Physical & Biological ResearchSIC 8731
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from OmniAb, Inc.
All →OmniAb Q3 2026 Results: Net Loss of $15.7M, Loss Narrows
OmniAb, Inc. reported total revenue of $31.8 million for the nine months ended September 30, 2026, a significant increase from $10.3 million in the prior year period, primarily driven by license and milestone revenue. Despite the revenue growth, the company recorded a net loss of $29.3 million for the first nine months of 2026, though this was an improvement over the $50.6 million net loss reported for the same period in 2025.
- Key figure
- Net loss $15.7M
OmniAb Financial Results
OmniAb reported Q3 2026 financial results, featuring revenue of $4.0 million and a net loss of $15.7 million. The company raised its full-year 2026 revenue guidance to $37-$39 million, citing strong licensing execution and momentum from its xPloration and OmniTides technologies.
“Our strong third-quarter 2026 performance reflects our licensing execution and our focus on driving value for our stakeholders within an efficient business model built on highly differentiated technologies.”
Matt Foehr, Chief Executive Officer of OmniAb
“In addition, the expanded commercial launch of xPloration®, the introduction of OmniTides™, and continued progress across our portfolio of milestone- and royalty-bearing partnered programs reinforce our confidence in the durability of our revenue base and our long-term growth potential. Based on our performance to date and our expectation for the remainder of the year, we are again raising our revenue guidance and cash outlook.”
Matt Foehr, Chief Executive Officer of OmniAb